Furthermore, Clovis Oncology has initiated a clinical evaluation of 68Ga-FAP-2286 (NCT04621435), which, as of June 2022, encompassed 48 patients with cancers of the breast, bladder, prostate, colon, head/neck, pancreas, sarcoma, cholangiocarcinoma, and lung [225]. The gene discussed is FAP; the disease is sarcoma.